[Treatment of severe asthma with anti-immunoglobulin E (Omalizumab). A new possibility in pulmonary medicine].
Xolair has recently been approved for the treatment of patients with inadequately controlled severe asthma. Three unstable atopic asthmatics, treated with high doses of inhaled steroid, nasal steoids, Montelukast or systemic corticosteroids, were offered injections with Xolair. Median IgE values were 200 kU/L. All three patients tolerated the treatment well with considerable clinical improvement (during 6 months). In this clinical setting, treatment with Xolair was successfully carried out in a respiratory out-patient clinic.
Nolte
Hendrik
H
Bispebjerg Hospital, Lungemedicinsk Klinik L.
Harving
Henrik
H
Backer
Vibeke
V
D000328:Adult; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D000069444:Omalizumab; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab